A Study of CRV431 Dosed Once Daily in NASH Induced F2 and F3 Subjects

Key Inclusion Criteria: * Male or female between 18 and 75 years of age (inclusive). * Capable of giving written informed consent and able to effectively communicate with the investigator and study personnel. * Presumed F2/F3 NASH to include: AST \>20 IU/L, Pro-C3 \>15.5 ng/mL, enhanced liver fibrosis (ELF) score \>9.8, and FibroScan \>8.5 kPa values. Key Exclusion Criteria: * Pregnant or breastfeeding or planning to become pregnant during the study period. * Known allergy to CRV431, cyclosporine, or any of their inactive ingredients. * Positive test for hepatitis B surface antigen (HBsAg), hepatitis C virus antibodies (HCVAb) or human immunodeficiency virus antibodies (HIVAb). * Well documented causes of chronic liver disease according to standard diagnostic procedures to include any history or presence of decompensated cirrhosis. * Subjects with a platelet count \<150,000/mL. * Subjects with hemoglobin A1c(HbA1c) \>9.5%. * Weight loss of more than 5% within 3 months prior to randomization. * Subjects with a blood pressure to include a systolic pressure \>150 or a diastolic pressure \>90. * At Screening, an estimated glomerular filtration rate (eGFR) \<60 mL/min/1.73 mL (calculated by the Chronic Kidney Disease Epidemiology Collaboration \[CKD-EPI\] method) and/or a Kidney Disease Improving Global Outcomes (KDIGO) category of \>G2. * Subjects with a history of organ transplantation. Corneal transplantation will be allowed.